Marvin L. White, President and Chief Executive Officer
Mr. White has served as President and Chief Executive Officer, and as a Board Member of Aptevo Therapeutics since August 2016. Previously, Mr. White served as Chief Financial Officer of St. Vincent Health, and was responsible for finance, patient financial services and managed care for all 19 hospitals and 36 joint ventures. Prior to St. Vincent Health, Mr. White served as Chief Financial Officer of LillyUSA, a subsidiary of Eli Lilly and Company, where he also held leadership positions in Corporate Finance and Investment Banking. Prior to his career in healthcare, Mr. White held leadership positions at General Motors, Hewlett-Packard, and Motorola, including financial roles within its Japan, South Asia, and Latin America Cellular Group. He is currently a Director of the Board at OneAmerica Financial Partners, Delta Dental of Washington and Emergent Biosolutions. Mr. White earned his B.S. in Accounting from Wilberforce University, an HBCU, and received an M.B.A. in Finance from Indiana University where he was awarded the Consortium Fellowship.


Jeff Lamothe, EVP and Chief Operating Officer
Mr. Lamothe leads the Clinical, Research & Development, Quality, Manufacturing and Operations organizations. He previously served as Aptevo’s EVP and Chief Financial Officer, leading Finance, Business Development, Investor Relations and IT. Prior to Aptevo, he was VP Finance in the Biosciences Division at Emergent BioSolutions. Mr. Lamothe assumed this role in 2014 when Emergent concluded the acquisition of Cangene Corporation, where he was Chief Financial Officer. Mr. Lamothe’s business experience is built on a 25+ year career, spanning several industries as both CFO and CEO roles. Prior to Cangene Corporation, Mr. Lamothe was the Chief Financial Officer of Smith Carter Architects and Engineers Incorporated. He also previously served as President and Chief Executive Officer of Kitchen Craft Cabinetry, after occupying the position of VP of Finance and Chief Financial Officer with the organization. Mr. Lamothe’s other past experience includes serving as Chief Financial Officer of Motor Coach Industries and he has held various roles at James Richardson & Sons, Limited and Ernst & Young LLP.



dirk-huebnerDirk Huebner, M.D., Chief Medical Officer*
Dr. Huebner is a Medical Advisor Consultant with approximately 29 years of academic and industry- based clinical drug development experience in the biotech and pharmaceutical industries. In the course of his career, he has led multiple clinical programs spanning all stages of development from Phase 1 through Phase 3 registration trials.

Before becoming a consultant Dr. Huebner served as CMO and Senior Medical Advisor for Mersana from November 2018 to January 2021, where he built their clinical development department and oversaw the development of their ADC pipeline. Prior to joining Mersana, Dr. Huebner served as Vice President, Head of Development, for Boston Biomedical where he assembled a robust clinical development team and oversaw the clinical development of multiple early stage compounds and the napabucasin phase 3 program.

Prior to his tenure at Boston Biomedical, Dr. Huebner spent six years with Millennium/Takeda Oncology as Executive Medical Director. During Dr. Huebner’s tenure at Takeda Oncology, he served as the global clinical lead for ADCETRIS® (brentuximab vedotin), an ADC that is indicated for the treatment of Hodgkin lymphoma and certain CD30 positive T-cell lymphomas. In that role, he led the regulatory approval of ADCETRIS® in Europe and the design and implementation of the subsequent registration-enabling studies for the compound. Prior to Takeda, he served as the clinical lead of clofarabine and its development in AML at Genzyme and held roles of increasing leadership and responsibility in global clinical drug development at Roche and Bristol-Myers Squibb.

Dr. Huebner received his Medical Doctor degree from Freie Universitaet Berlin, Germany and pursued a medical residency in the Department of Urology, University Hospital Eppendorf, Hamburg.


Jane Gross, Ph.D., Chief Scientific Officer*
Dr. Gross leads research and non-clinical development focusing on the development of novel protein therapeutics based on the ADAPTIR™ platform, a position she has held for the last five years at Emergent. She leads research efforts in molecular biology and protein engineering, immunology, protein and cell sciences, and translational research for clinical development. Dr. Gross has a Ph.D. in Immunology and over twenty-five years of experience in the discovery and development of novel protein therapeutics in autoimmune, infectious disease and oncology indications and is an inventor on over 100 patents. Prior to joining Emergent, Dr. Gross served as VP of Immunology Research at ZymoGenetics Inc., where she led efforts in discovery and development of therapeutics from novel genes for treatment of AIID and cancer.




SoYoung Kwon, SVP, General Counsel, Business Development and Corporate Affairs
Ms. Kwon leads the Legal, Compliance, Business Development and Human Resources functions at Aptevo, overseeing all aspects of corporate governance, securities, compliance, contractual and intellectual property matters along with talent acquisition, compensation and benefits, performance management, learning and development. She brings more than 20 years of experience across industries including insurance, high-tech and biologics, gene and cell therapy, advising executives and boards of directors of companies ranging from startups to Fortune 500 companies. Prior to joining Aptevo, Ms. Kwon served as the Global SVP, General Counsel and Corporate Secretary at AGC Biologics, a contract development and manufacturing organization with facilities in the U.S., Europe, and Asia. Ms. Kwon also served as VP, General Counsel and Corporate Secretary at Onvia, Inc., Senior Counsel at Safeco Corporation, and a Corporate Associate at Graham & Dunn PC. Ms. Kwon is active in her community by serving on the Education and Community Engagement Committee of the Seattle Art Museum and as President of the Washington Scholarship Foundation.



Daphne Taylor, SVP and Chief Financial Officer
Ms. Taylor leads Finance, Investor Relations, and IT and previously served as Aptevo’s Senior Vice President of Finance where she held responsibility for all strategic planning and budgeting, treasury activities, internal and external reporting, and financial compliance. Prior to Aptevo, Daphne’s career includes 25 years of financial experience in the life sciences and technology industries. Prior to joining Aptevo, Ms. Taylor served as Chief Financial Officer at BioLife Solutions. She also served as VP, Chief Accounting Officer, and Controller at Cardiac Science Corporation and in multiple other roles, including Controller at LookSmart, SpeedTrak, CoreMark International and Pacific Telesis. Ms. Taylor began her career at Coopers & Lybrand in San Francisco. She is active in her community and serves on the Finance Committee of the Northshore Schools Foundation. Ms. Taylor holds a B.A. from Sonoma State University and is a Licensed CPA in Washington and California.



*Drs. Huebner and Gross are consultants to the Company.